Pitolisant
- Half-Life (t½)
- PO: 20h
- Formula
- C17H26ClNO
- Molecular Weight
- 295.8 g/mol
- Aliases
- Wakix
Pharmacological Mechanism
Histamine H3 receptor antagonist / inverse agonist; raises central histamine to promote wakefulness (narcolepsy). CYP2D6 + CYP3A4 metabolism.
Half-Life & Elimination Curve (PO: 20h)
Plasma (PO)t½ Decay (20h)Effect Site (ke0)
- 0×t½0h100% (20.3 µg/L)
- 1×t½20h50% (10.1 µg/L)
- 2×t½40h25% (5.07 µg/L)
- 3×t½60h12.5% (2.54 µg/L)
- 4×t½3.3d6.3% (1.27 µg/L)
- 5×t½4.2d3.1% (0.634 µg/L)
Dosing Guidelines
- Oral (PO): Typical 17.8 mg (Range: 17.8–35.6 mg)
Pharmacokinetic Parameters
- Oral (PO): Bioavailability (F): 90% · Volume of Distribution (Vd): 700 L · Absorption (ka): 1 h⁻¹ (t½ka ≈ 42m)
- Effect-Site Equilibration (ke0): 0.5 h⁻¹ (equilibration half-time t½ke0 ≈ 1.39h)
Receptor Binding & Occupancy
Target Organ Systems
Notes
PK from FDA prescribing information (DailyMed setid 8daa5562-824e-476c-9652-26ceef3d4b0e): oral absorption ~90% (F 0.9), Vd 5–10 L/kg (~700 L), terminal t½ ~20 h, Tmax 3.5 h, CYP2D6/3A4. ka_hr 1.0 derived from Tmax 3.5 h (ke from t½ 20 h).
Chemical Structure & Identifiers
- InChIKey: NNACHAUCXXVJSP-UHFFFAOYSA-N
- SMILES: C1CCN(CC1)CCCOCCCC2=CC=C(C=C2)Cl
References